Roche’s Genentech Breaks Ground on US Manufacturing Facility in North Carolina

700-Million-Dollar Project Roche’s Genentech Breaks Ground on US Manufacturing Facility in North Carolina

2025-08-27 Source: Press release Roche 2 min Reading Time

Related Vendors

Roche Diagnostics International AG

Glatt Ingenieurtechnik GmbH

TRM Filter d.o.o.

ProMinent GmbH

Roche’s US subsidiary Genentech has broken ground on a new manufacturing facility in Holly Springs, North Carolina. The 700-million-dollar project is expected to support the production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.

Basel/Switzerland – Genentech, a member of the Roche Group has recently broken ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast. The 65,000 m² facility is strategically designed to support production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.

Genentech’s initial investment in North Carolina is estimated at more than 700 million dollars and is part of Roche’s 50-billion-dollar commitment to invest in US manufacturing infrastructure and R&D. The facility will create more than 1,900 jobs.

Roche Group CEO Thomas Schinecker: “I am proud to break ground on our new state-of-the-art manufacturing facility in North Carolina, which will support the production of our next-generation obesity treatments. This 700-million-dollar project is an integral part of our broader 50-billion-dollar commitment to further expand our already significant presence in the United States, building on our 120-year legacy of driving innovation and creating jobs across America. I am excited about the impact this facility will have on delivering life-changing medicines to patients in the US and around the world.”

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

The company selected Holly Springs in North Carolina, a growing hub for biopharmaceutical innovation, for its highly skilled local workforce, strong academic institutions and proximity to other leading life science companies.

The new facility is expected to be completed and operational by 2029, incorporating modern biomanufacturing technologies, as well as advanced automation and digital capabilities. The 400,000 m² lot includes space for future expansion.

Designed for high-volume, efficient, and sustainable production, the new facility will increase Roche’s manufacturing capacity and enhance supply chain resilience. It complements Roche’s manufacturing sites around the world, including in Europe and Switzerland, to efficiently serve patients where they are.

(ID:50527505)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.